Attune Pharma
250 West 55th Street
Suite 16B
New York
New York
10019
United States
Website: http://attunepharma.com
Email: info@attunepharma.com
About Attune Pharma
Attune Pharmaceuticals is a pre-clinical stage biotechnology focused on the discovery and development of novel oral once-daily small molecule therapeutics for treatment of rare diseases. Attune Pharmaceuticals is currently developing 2 programs in rare diseases: Hereditary angioedema (HAE) and complement-mediated diseases. Attune Pharmaceuticals has identified ATN-249 as a lead candidate to treat HAE and will begin clinical testing in 2017.LEADERSHIP:
CEO: Andrew McDonald
CMO: Ira N. Kalfus
CLINICAL TRIAL:
Please click here for clinical trial information.
5 articles about Attune Pharma
-
Clinical Study Published In Resuscitation Demonstrates Efficacy And Safety Of Attune’s EnsoETM For Cooling And Rewarming Patients
10/6/2017
-
Breakthrough Medical Device Start-up Attune Names Industry Veteran Keith Warner As COO
6/20/2017
-
Attune Announces Positive Data From Recent Pre-Clinical Studies For ATN-249, An Oral Plasma Kallikrein Inhibitor For The Treatment Of HAE At C1-INH Deficiency Workshop
5/22/2017
-
Attune Announces Pre-Clinical Data For ATN-249, An Oral Plasma Kallikrein Inhibitor For The Treatment Of HAE At AAAAI
3/6/2017
-
Attune Announces Late-Breaking Poster Presentation Of ATN-249, An Oral Kallikrein Inhibitor For The Treatment Of HAE
3/1/2017